Quarterly report · Q2
4543.TEDINET S100S9UJ
Period2023-04-01 → 2023-09-30
Filed2023-11-14
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥443.9bn | 2023-04-01 → 2023-09-30 | Cons. | Revenue IFRS |
| Revenue | ¥228.6bn | 2023-07-01 → 2023-09-30d | Cons. | Revenue IFRS |
| Revenue | ¥820.2bn | 2022-04-01 → 2023-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥403.3bn | 2022-04-01 → 2022-09-30 | Cons. | Revenue IFRS |
| Revenue | ¥206.0bn | 2022-07-01 → 2022-09-30d | Cons. | Revenue IFRS |
| Operating income | ¥66.5bn | 2023-04-01 → 2023-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥36.8bn | 2023-07-01 → 2023-09-30d | Cons. | Operating profit loss IFRS |
| Operating income | ¥56.0bn | 2022-04-01 → 2022-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥25.5bn | 2022-07-01 → 2022-09-30d | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥66.4bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥36.6bn | 2023-07-01 → 2023-09-30d | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥116.1bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥54.6bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥25.0bn | 2022-07-01 → 2022-09-30d | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥50.1bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥27.5bn | 2023-07-01 → 2023-09-30d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥89.3bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥40.3bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥17.9bn | 2022-07-01 → 2022-09-30d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥50.1bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss IFRS |
| Net income | ¥27.5bn | 2023-07-01 → 2023-09-30d | Cons. | Profit loss IFRS |
| Net income | ¥40.3bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss IFRS |
| Net income | ¥17.9bn | 2022-07-01 → 2022-09-30d | Cons. | Profit loss IFRS |
| Total assets | ¥1.75T | at 2023-09-30 | Cons. | Assets IFRS |
| Total assets | ¥1.60T | at 2023-03-31 | Cons. | Assets IFRS |
| Total assets | ¥1.66T | at 2022-09-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥487.4bn | at 2023-09-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥491.2bn | at 2023-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥1.26T | at 2023-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.11T | at 2023-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.17T | at 2022-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.01T | at 2022-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥1.26T | at 2023-09-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥1.11T | at 2023-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥1.17T | at 2022-09-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥187.3bn | at 2023-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥187.3bn | at 2023-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥212.6bn | at 2022-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥205.3bn | at 2022-03-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥53.6bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥117.5bn | 2022-04-01 → 2023-03-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥60.3bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥36.1bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥59.1bn | 2022-04-01 → 2023-03-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥31.6bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥30.0bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥86.6bn | 2022-04-01 → 2023-03-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥37.9bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥67.27 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥36.99 | 2023-07-01 → 2023-09-30d | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥119 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥53.37 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥23.75 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥67.24 | 2023-04-01 → 2023-09-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥36.97 | 2023-07-01 → 2023-09-30d | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥118.95 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥53.35 | 2022-04-01 → 2022-09-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥23.74 | 2022-07-01 → 2022-09-30d | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 72.1% | at 2023-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 69.3% | at 2023-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 70.6% | at 2022-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 20
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue external | 2023-04-01 → 2023-09-30 | ¥119m |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-09-30 | −¥1.0bn |
| jpcrp040300-q2r_E01630-000Blood And Cell Technologies Companyreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥84.1bn |
| jpcrp040300-q2r_E01630-000Blood And Cell Technologies Companyreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥10.6bn |
| jpcrp040300-q2r_E01630-000Cardiac And Vascular Companyreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥265.7bn |
| jpcrp040300-q2r_E01630-000Cardiac And Vascular Companyreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥57.6bn |
| jpcrp040300-q2r_E01630-000Medical Care Solutions Companyreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥94.0bn |
| jpcrp040300-q2r_E01630-000Medical Care Solutions Companyreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥8.3bn |
| —segment total | revenue external | 2023-04-01 → 2023-09-30 | ¥443.8bn |
| —segment total | segment profit | 2023-04-01 → 2023-09-30 | ¥76.6bn |
| Reconciling Itemsreconciling | revenue external | 2022-04-01 → 2022-09-30 | ¥124m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-09-30 | ¥275m |
| jpcrp040300-q2r_E01630-000Blood And Cell Technologies Companyreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥74.0bn |
| jpcrp040300-q2r_E01630-000Blood And Cell Technologies Companyreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥9.1bn |
| jpcrp040300-q2r_E01630-000Cardiac And Vascular Companyreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥235.4bn |
| jpcrp040300-q2r_E01630-000Cardiac And Vascular Companyreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥52.9bn |
| jpcrp040300-q2r_E01630-000Medical Care Solutions Companyreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥93.8bn |
| jpcrp040300-q2r_E01630-000Medical Care Solutions Companyreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥8.1bn |
| —segment total | revenue external | 2022-04-01 → 2022-09-30 | ¥403.2bn |
| —segment total | segment profit | 2022-04-01 → 2022-09-30 | ¥70.2bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 690
| Item | Context | Value | Unit |
|---|---|---|---|
| Cash and cash equivalents IFRS (5-year summary) | Prior1YearInstant | 187322000000 | JPY |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 747682540 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 747682540 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 747682540 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 747682540 | |
| Number of shares held | CurrentQuarterInstant_No1MajorShareholdersMember | 157818000 | |
| Shareholding ratio | CurrentQuarterInstant_No1MajorShareholdersMember | 0.2119 | |
| Number of shares held | CurrentQuarterInstant_No2MajorShareholdersMember | 72874000 | |
| Shareholding ratio | CurrentQuarterInstant_No2MajorShareholdersMember | 0.0979 | |
| Number of shares held | CurrentQuarterInstant_No3MajorShareholdersMember | 31384000 | |
| Shareholding ratio | CurrentQuarterInstant_No3MajorShareholdersMember | 0.0421 | |
| Number of shares held | CurrentQuarterInstant_No4MajorShareholdersMember | 24422000 | |
| Shareholding ratio | CurrentQuarterInstant_No4MajorShareholdersMember | 0.0328 | |
| Number of shares held | CurrentQuarterInstant_No5MajorShareholdersMember | 14720000 | |
| Shareholding ratio | CurrentQuarterInstant_No5MajorShareholdersMember | 0.0198 | |
| Number of shares held | CurrentQuarterInstant_No6MajorShareholdersMember | 12859000 | |
| Shareholding ratio | CurrentQuarterInstant_No6MajorShareholdersMember | 0.0173 | |
| Number of shares held | CurrentQuarterInstant_No7MajorShareholdersMember | 12640000 | |
| Shareholding ratio | CurrentQuarterInstant_No7MajorShareholdersMember | 0.0170 | |
| Number of shares held | CurrentQuarterInstant_No8MajorShareholdersMember | 12461000 | |
| Shareholding ratio | CurrentQuarterInstant_No8MajorShareholdersMember | 0.0167 | |
| Number of shares held | CurrentQuarterInstant_No9MajorShareholdersMember | 11228000 | |
| Shareholding ratio | CurrentQuarterInstant_No9MajorShareholdersMember | 0.0151 | |
| Number of shares held | CurrentQuarterInstant_No10MajorShareholdersMember | 10653000 | |
| Shareholding ratio | CurrentQuarterInstant_No10MajorShareholdersMember | 0.0143 | |
| Number of shares held | CurrentQuarterInstant | 361059000 | |
| Shareholding ratio | CurrentQuarterInstant | 0.4848 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithNoVotingRightsMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember | 2979300 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 7445442 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 744544200 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember | 159040 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant | 747682540 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant | 7445442 | |
| Number of shares held in own name treasury shares etc | CurrentQuarterInstant_Row1Member | 2979300 | |
| Number of shares held in others names treasury shares etc | CurrentQuarterInstant_Row1Member | － | |
| Total number of shares held treasury shares etc | CurrentQuarterInstant_Row1Member | 2979300 | |
| Shareholding ratio treasury shares etc | CurrentQuarterInstant_Row1Member | 0.004 | |
| Number of shares held in own name treasury shares etc | CurrentQuarterInstant | 2979300 | |
| Number of shares held in others names treasury shares etc | CurrentQuarterInstant | － | |
| Total number of shares held treasury shares etc | CurrentQuarterInstant | 2979300 | |
| Shareholding ratio treasury shares etc | CurrentQuarterInstant | 0.004 | |
| Cash and cash equivalents IFRS | Prior1YearInstant | 187322000000 | JPY |
| Cash and cash equivalents IFRS | CurrentQuarterInstant | 187313000000 | JPY |
| Trade and other receivables ca IFRS | Prior1YearInstant | 150635000000 | JPY |
| Trade and other receivables ca IFRS | CurrentQuarterInstant | 167532000000 | JPY |
| Other financial assets ca IFRS | Prior1YearInstant | 106000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 16 of 16 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |